Thomas C.
- Country
- France
- Department
- 2409: Hématologie
Research Overview
- A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
- Evaluation of Blinatumomab, Isatuximab, and Ponatinib in Frontline Therapy for Adults with Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma
- A Phase 1/2 Study of Enzomenib (DSP 5336) in Adults with Relapsed or Refractory Acute Leukemia, Including MLL-Rearranged or NPM1-Mutated Subtypes
Data & Insights
Has run more than one trial at 304 of 510 partner sites.
Specializations
Acute Myeloid Leukemia Research
The investigator specializes in treating relapsed and refractory acute myeloid leukemia (AML), with particular focus on cases involving NPM1 mutations and KMT2A rearrangements. Their research extends to MEIS1 overexpression mutations in AML patients.
- Novel therapeutic approaches for R/R AML
- Mutation-specific treatment strategies
- Menin-MLL inhibitor studies
Myelodysplastic Syndrome Studies
The investigator conducts extensive research in myelodysplastic syndromes (MDS), covering both higher-risk and lower-risk variants. Their work includes studies on IDH2-mutated MDS and transfusion-dependent anemia in MDS patients.
- Treatment strategies for transplant-ineligible patients
- Novel combination therapies
- Erythroid response optimization
Therapeutic Innovation
The investigator leads research in novel therapeutic approaches, including hypomethylating agent-based treatments and targeted molecular therapies. Their work encompasses the development of IRAK4 inhibitors and telomerase inhibitors.
- Drug resistance mechanisms
- Combination therapy development
- Molecular targeting strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.